Adagene ADAG Stock
Adagene Price Chart
Adagene ADAG Financial and Trading Overview
| Adagene stock price | 1.43 USD |
| Previous Close | 1.19 USD |
| Open | 1.2 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 900 |
| Day's Range | 1.16 - 1.21 USD |
| 52 Week Range | 0.9 - 2.1 USD |
| Volume | 799 USD |
| Avg. Volume | 26.84K USD |
| Market Cap | 52.32M USD |
| Beta (5Y Monthly) | 0.201751 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.53 USD |
ADAG Valuation Measures
| Enterprise Value | -66349400 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.61608243 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.6299024 |
| Price/Book (mrq) | 0.6183135 |
| Enterprise Value/Revenue | -7.14 |
| Enterprise Value/EBITDA | 0.805 |
Trading Information
Adagene Stock Price History
| Beta (5Y Monthly) | 0.201751 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 2.1 USD |
| 52 Week Low | 0.9 USD |
| 50-Day Moving Average | 1.37 USD |
| 200-Day Moving Average | 1.42 USD |
ADAG Share Statistics
| Avg. Volume (3 month) | 26.84K USD |
| Avg. Daily Volume (10-Days) | 13.21K USD |
| Shares Outstanding | 43.77M |
| Float | 16.55M |
| Short Ratio | 0.83 |
| % Held by Insiders | 10.59% |
| % Held by Institutions | 9.56% |
| Shares Short | 19.69K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.040% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -903.078% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.68% |
| Return on Equity (ttm) | -66.74% |
Income Statement
| Revenue (ttm) | 9.29M USD |
| Revenue Per Share (ttm) | 0.22 USD |
| Quarterly Revenue Growth (yoy) | -39.10% |
| Gross Profit (ttm) | N/A |
| EBITDA | -82471152 USD |
| Net Income Avi to Common (ttm) | -79971848 USD |
| Diluted EPS (ttm) | -1.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 143.76M USD |
| Total Cash Per Share (mrq) | 3.34 USD |
| Total Debt (mrq) | 27.97M USD |
| Total Debt/Equity (mrq) | 33.66 USD |
| Current Ratio (mrq) | 2.711 |
| Book Value Per Share (mrq) | 1.933 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -48611688 USD |
| Levered Free Cash Flow (ttm) | -19613868 USD |
Profile of Adagene
| Country | United States |
| State | N/A |
| City | Suzhou |
| Address | Building C14 |
| ZIP | 215123 |
| Phone | 86 512 8777 3632 |
| Website | https://www.adagene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 248 |
Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Q&A For Adagene Stock
What is a current ADAG stock price?
Adagene ADAG stock price today per share is 1.43 USD.
How to purchase Adagene stock?
You can buy ADAG shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adagene?
The stock symbol or ticker of Adagene is ADAG.
Which industry does the Adagene company belong to?
The Adagene industry is Biotechnology.
How many shares does Adagene have in circulation?
The max supply of Adagene shares is 47.11M.
What is Adagene Price to Earnings Ratio (PE Ratio)?
Adagene PE Ratio is now.
What was Adagene earnings per share over the trailing 12 months (TTM)?
Adagene EPS is -0.74 USD over the trailing 12 months.
Which sector does the Adagene company belong to?
The Adagene sector is Healthcare.
Adagene ADAG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17210.8 USD — |
-0.99
|
7.12B USD — | 17128.71 USD — | 17467.35 USD — | — - | 7.12B USD — |
| NASDAQ Global Market Composite NQGM | 1841.99 USD — |
+0.12
|
— — | 1835.2 USD — | 1871.93 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 924.43 USD — |
+0.1
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}